Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours

Anticancer Research

Volumn 16, Issue 5 B, 1996, Pages 3089-3095

  Baars, J W ^a,d   Holtkamp, M J ^a   Nooyen, W J ^a   Walll, E V D ^a,b   Te Velde, A ^a   Dalesio, O ^a   Slaper Cortenbach, I C M ^a   Schoot, E V D ^a   Richel, D J ^a,c   Gerritsen, W R ^a   Schornagel, J H ^a   Rodenhuis, S ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Bone marrow recovery; Etoposide; G CSF; GD34; Ifosfamide; Stem cell mobilisation

Indexed keywords

CD34 ANTIGEN; ETOPOSIDE; IFOSFAMIDE; MESNA; PARACETAMOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGE; ALOPECIA; ARTICLE; BONE PAIN; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GENDER; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; LYMPHOMA; MALE; MULTIVARIATE ANALYSIS; MYALGIA; PRIORITY JOURNAL; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ETOPOSIDE; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IFOSFAMIDE; LEUKAPHERESIS; LYMPHOMA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; TRANSPLANTATION CONDITIONING;

EID: 10544228950     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD: Autologous peripheral hematopoietic stem cell trans-plantation restores hematopoietic function following marrow ablative therapy. Blood 71: 723-727, 1988.
2. Gianni AM: Where do we stand with respect to the use of peripheral blood stem cells? Ann Oncol 5: 781-784, 1994.
3. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy:influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 12: 28-36, 1994.
4. To LB, Roberts MM. Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 9: 277-284, 1992.
5. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilized by filgastrim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339: 640-644, 1992.
6. Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D: Effects of recombinant granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72: 2074-2081, 1988.
7. Siena S, Bregni M, Brando B, Ravagnani F, Bonnadonna G, Gianni AM: Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 74: 1905-1914, 1989.
8. Brugger W, Bross K, Frisch J, Dem P et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colonystimulating factor following polychemotherapy with etoposide, ifosfamide and cisplatin. Blood 79: 1193-1200, 1992.
9. Van Hoef MEHM. Review of the literature on PBPC mobilization:recommendation for efficient PBPC collection. Blood 84. suppl 1: 739a, abstract 2941, 1994.
10. Pettengell R, Testa NG, Swindell R, Crowther D, Dexter TM. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 82: 2239-2248, 1993.
11. Williams SD, Einhorn LH, Greco FA et al. VP-16-213 salvage therapy for refractory germinal neoplasms. Cancer 46: 2154-2158, 1980.
12. Wheeler BM, Loehrer PJ, Williams SD, Einhorn LH: Ifosfamide in refractory germ cell tumors. J Clin Oncol 4: 28-34, 1986.
13. Loehrer PJ, Einhorn LH, Williams SD: Salvage therapy for refractory germ cell tumors with VP-16+ifosfamide+cisplatin. J Clin Oncol 4: 528-536, 1986.
14. Hagemeister FB, Tannir N, Mc Laughlin P et al. MIME chemotherapy (Methyl-GAG, ifosfamide, methotrexate, etoposide) as a treatment for recurrent Hodgkin's disease. J Clin Oncol 5: 556-561, 1987.
15. Cahanillas F, Hagemeister FB, Mc Laughlin P et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5: 407-412, 1987.
16. Huygens PC, Ossenkoppele GJ, v.d. Lelie J, Thomas LLM, Wijngaarden MJ, Slaper ICM: IVMP-16 followed by high-dose chemotherapy and autologous bone marrow transplantation as salvage treatment for malignant lymphoma. Hematological Oncology 9: 245-251, 1991.
17. Loehrer PJ Sr, Lauer R, Roth BJ et al. Salvage therapy in recurrent germ cell cancer:Ifosfamide and cisplatinum plus either vinblastin or etoposide. Ann Intern Med 102: 540-546, 1988.
18. Kamen BA, Frenkel E, Colvin OM. Ifosfamide:should the honeymoon be over?. J Clin Oncol 13: 307-309, 1995.
19. v.d. Wall E, Richel DJ, Holtkamp MJ et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: Effect of graft size. Ann Oncol 5: 795-802, 1994.
20. Dercksen MW, Rodenhuis S, Dirkson MKA et al. Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stemcell transplantation. J Clin Oncol 13: 1922-1932, 1995.
21. Haas R., Mohle R, Fruhlauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83: 3787-3794, 1994.
22. Wintrobe MW. Origin and development of the blood and bloodforming tissues. In Wintrobe MW, editor: Clinical Hematology, Lea and Febiger Philadelphia, 8th edition, 52: 1981.
23. Shea TC, Mason JR, Breslin M, Bissent E, Muller M, Taetle R. Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitors in patients receiving multiple cycles of high-dose chemotherapy. J Clin Oncol 12: 1012-1020, 1994.
24. Hornung RL, Longo DL. Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood 80: 77-83, 1992.
25. Hoglund M, Bengtsson M, Simonsson B, Smedmyr B, Totterman T. Leukapheresis with peripheral blood progenitor cell (PBPC) harvest in healthy volunteers recieving different doses of lenograstim-evidence of a dose response effect. Blood 84, suppl 1: 348a. abstract 1377, 1994.